8-K: Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio announces its Q1 2025 financial results and provides updates on its clinical programs, including upcoming data readouts for ADI-001 and ADI-270 in the second half of 2025.

Summary

• Adicet Bio reported its financial results for the first quarter of 2025.
• The company is advancing its pipeline of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
• Preliminary Phase 1 data for ADI-001 in autoimmune diseases and ADI-270 in ccRCC are expected in the second half of 2025, with more than 6 patients with at least 3-month follow up in both programs.
• Enrollment is open for lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients in the Phase 1 clinical trial of ADI-001.
• The company expects to initiate enrollment for patients with systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) in the Phase 1 trial in 3Q/2025.
• Patient enrollment is ongoing in the Phase 1 trial of ADI-270 in metastatic/advanced ccRCC.
• R&D expenses were $22.8 million for the three months ended March 31, 2025, compared to $23.9 million during the same period in 2024.
• G&A expenses were $7.1 million for the three months ended March 31, 2025, compared to $7.0 million for the same period in 2024.
• Net loss for the three months ended March 31, 2025 was $28.2 million, or a net loss of $0.31 per basic and diluted share.
• Cash and cash equivalents were $150.4 million as of March 31, 2025, compared to $176.3 million as of December 31, 2024.
• The company expects its current cash to fund operating expenses into the second half of 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the upcoming data readouts, FDA Fast Track Designation, and sufficient cash runway. However, the net loss and decrease in cash position temper the overall sentiment.

Positives

• Adicet Bio is advancing its pipeline of allogeneic gamma delta T cell therapies.
• The company has two programs with clinical data readouts expected in the second half of 2025.
• ADI-001 received Fast Track Designation from the FDA for two indications.
• The company's cash position is expected to fund operations into the second half of 2026.
• Michael Grissinger's appointment to the Board of Directors brings significant expertise in biopharmaceutical business development.

Negatives

• The company reported a net loss of $28.2 million for the first quarter of 2025.
• Cash and cash equivalents decreased from $176.3 million at the end of 2024 to $150.4 million as of March 31, 2025.
• R&D expenses, while decreased compared to the same period in 2024, still represent a significant cost.

Risks

• The timing and success of clinical trials are subject to various risks and uncertainties.
• Clinical studies may fail to demonstrate adequate safety and efficacy of Adicet's product candidates.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company's ability to meet production and product release expectations is not guaranteed.
• Global economic conditions and public health emergencies could impact Adicet's business and financial results.

Future Outlook

Adicet Bio anticipates significant data milestones in the second half of 2025 with preliminary Phase 1 data from ADI-001 in autoimmune diseases and ADI-270 in ccRCC. The company believes its cash position will fund operations into the second half of 2026.

Management Comments

• We are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon, said Chen Schor, President and Chief Executive Officer of Adicet Bio.
• In the second half of 2025, we expect to report preliminary Phase 1 data from our two lead programs ADI-001 in autoimmune diseases and ADI-270 in ccRCC, with more than 6 patients with at least 3-month follow up in both programs.
• As we progress toward these readouts, we also look to harness the full potential of our allogeneic gamma delta 1 CAR T cell therapy platform, which we believe has key advantages over other cell types.
• We have identified two promising highly differentiated programs, one targeting PSMA and one follow-on program targeting autoimmune diseases with potential to become best-in-class therapies for patients fighting autoimmune diseases and cancer.

Industry Context

Adicet Bio is operating in the competitive fields of allogeneic cell therapies and immuno-oncology. The company's focus on gamma delta T cells and CAR-T technology positions it alongside other companies developing novel cell therapies for cancer and autoimmune diseases. Success in clinical trials and regulatory approvals will be critical for Adicet to differentiate itself and gain market share.

Comparison to Industry Standards

• Adicet Bio's approach to allogeneic gamma delta T cell therapies is relatively novel compared to more established approaches using alpha-beta T cells, such as those developed by companies like Allogene Therapeutics.
• The clinical data readouts expected in the second half of 2025 will be crucial in determining the competitiveness of Adicet's programs compared to other cell therapy companies targeting similar indications.
• The cash runway into the second half of 2026 provides Adicet with a reasonable timeframe to achieve key milestones and potentially secure additional funding or partnerships.

Management Changes

Stakeholder Impact

• Shareholders: The upcoming data readouts and financial performance will impact shareholder value.
• Patients: The clinical trials offer potential new treatment options for autoimmune diseases and cancer.
• Employees: The company's progress and financial stability affect job security and opportunities.
• Investors: The cash runway and clinical milestones are important factors for investment decisions.

Next Steps

• Report preliminary Phase 1 data from ADI-001 in autoimmune diseases and ADI-270 in ccRCC in the second half of 2025.
• Initiate enrollment for patients with systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) in the Phase 1 trial in 3Q/2025.
• Present an oral abstract highlighting ADI-270 data at the ASGCT Annual Meeting in May 2025.

Key Dates

Keywords

ADI-001, ADI-270, Autoimmune diseases, ccRCC, Gamma delta T cell therapies, Clinical trial, Financial results, Adicet Bio